top of page

EC grants marketing authorisation to afatinib in SqCC of the lung

The European Commission (EC) has approved Boehringer Ingelheim’s Giotrif (afatinib) for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung. Specifically, afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page